Mr. Mucus helps Reckitt dominate cough-and-cold space

Carly Helfand What's the key to landing your brand on the leaderboard of cough-and-cold meds? Mr. Mucus, apparently. FiercePharma News

AstraZeneca spending hundreds of millions in China, blueprints new R&D hub

John Carroll FierceBiotech News

Discount sways U.K. cost gatekeeper on AstraZeneca’s ovarian cancer med Lynparza

Emily Wasserman AstraZeneca scored a victory for its ovarian cancer drug Lynparza, as U.K. cost watchdog the National Institute for Health and Care Excellence did an about-face and ...

NICE backs Astellas’ Xtandi in pre-chemo patients, but J&J’s Zytiga isn’t so lucky

Carly Helfand Astellas and Medivation's prostate cancer med Xtandi has been coming up strong behind Zytiga from Johnson & Johnson ever since hitting the market. And now, it's ...

UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, AstraZeneca has popped up ...

Will Glaxo’s peers follow its anti-corruption lead in China?

Carly Helfand GlaxoSmithKline, post-corruption scandal, has been working hard to clean up its act in China, overhauling its sales practices to wipe out bribery–and its general ...

Mylan latest caught up in DOJ probe of generic drug prices

Eric Palmer Mylan said today that it got a special delivery from the Justice Department Thursday, making it the most recent of a string of drugmakers to get a subpoena from federal ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

Lilly backs a $25M round for anti-inflammatory startup Symic

Damian Garde San Francisco's Symic raised $ 25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly to lead ...

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti

Carly Helfand After winning FDA approval Monday, the latest multiple myeloma treatment–Empliciti, from Bristol-Myers Squibb and AbbVie–is about to hit the scene. And like ...

Dr. Reddy’s blasted in warning letter for hiding existence of testing lab from FDA

Eric Palmer An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to ...

Lilly’s middling lung cancer drug wins FDA approval with a restrictive label

Damian Garde Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population ...
Page 5 of 204« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS